Proportional hazards model for risk of death
| HR | 95% CI | p Value | |
|---|---|---|---|
| Cohort (vs simvastatin monotherapy) | |||
| High-potency statin monotherapy | 0.72 | 0.59 to 0.88 | <0.001 |
| Ezetimibe/statin combination | 0.96 | 0.64 to 1.43 | 0.847 |
| Gender (female vs male) | 0.84 | 0.74 to 0.95 | 0.009 |
| Age (per year) | 1.08 | 1.08 to 1.09 | <0.001 |
| Smoker (yes vs no) | 1.44 | 1.25 to 1.65 | <0.001 |
| Diabetic (yes vs no) | 1.44 | 1.13 to 1.83 | <0.001 |
| Further MI during follow-up | 1.45 | 1.32 to 1.60 | <0.001 |
| Cardiovascular drugs (yes vs no) | |||
| Aspirin | 0.57 | 0.48 to 0.69 | <0.001 |
| β-Blockers | 0.68 | 0.59 to 0.79 | <0.001 |
| ACE-I | 0.72 | 0.62 to 0.84 | <0.001 |
| DHP CCB | 0.57 | 0.47 to 0.69 | <0.001 |
| Non-DHP CCB | 1.06 | 0.84 to 1.32 | 0.624 |
| Nitrate | 1.00 | 0.86 to 1.16 | 0.582 |
| Statin compliance | 0.94 | 0.93 to 0.94 | 0.428 |
Cardiovascular drug therapy and further myocardial infarction were considered as time-dependent covariants during study period.
ACE-I, angiotensin converting enzyme inhibitors; DHP CCB, dihydropyridine calcium channel blockers; MI, myocardial infarction.